Although inhibition of BACE1-mediated cleavage of APP remains an attractive therapeutic approach in AD, it appears that reducing BACE1-mediated generation of pathogenic Aβ peptides alone will not be sufficient to stop plaque growth53,54. Here, BACE1 is linked to Alzheimer disease.